China Neuroendocrine Tumor Drug Market Research Report 2018

February 2018 | 109 pages | ID: C0713195BD1QEN
QYResearch

Abstracts

The global Neuroendocrine Tumor Drug market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Neuroendocrine Tumor Drug development status and future trend in China, focuses on top players in China, also splits Neuroendocrine Tumor Drug by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include

• Eisai
• Exelixis, Inc.
• Foresee Pharmaceuticals, LLC
• Hutchison MediPharma Limited
• Intezyne, Inc
• INVENT Pharmaceuticals, Inc.
• Ipsen S.A.
• Jiangsu Hengrui Medicine Co., Ltd.
• Karyopharm Therapeutics, Inc.
• Lexicon Pharmaceuticals, Inc.
• Midatech Pharma Plc.
• Millennium Pharmaceuticals, Inc.
• MolMed S.p.A.
• Northwest Biotherapeutics, Inc.
• Novartis AG
• OctreoPharm Sciences GmbH
• OXiGENE, Inc.

Geographically, this report splits the China market into six regions,

• South China
• East China
• Southwest China
• Northeast China
• North China
• Central China
• Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into

• mTOR protein inhibitors
• Tyrosine kinase 3 inhibitors
• Somatostatin receptor antagonists
• Growth hormone releasing factor antagonists
• Somatostatin receptor agonists
• Others

On the basis of the end users/application, this report covers

• Hospital
• Clinic
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

China Neuroendocrine Tumor Drug Market Research Report 2017

1 NEUROENDOCRINE TUMOR DRUG OVERVIEW

1.1 Product Overview and Scope of Neuroendocrine Tumor Drug
1.2 Classification of Neuroendocrine Tumor Drug by Product Category
  1.2.1 China Neuroendocrine Tumor Drug Sales (K Pcs) Comparison by Type (2012-2022)
  1.2.2 China Neuroendocrine Tumor Drug Sales (K Pcs) Market Share by Type in 2016
  1.2.3 mTOR protein inhibitors
  1.2.4 Tyrosine kinase 3 inhibitors
  1.2.5 Somatostatin receptor antagonists
  1.2.6 Growth hormone releasing factor antagonists
  1.2.7 Somatostatin receptor agonists
  1.2.8 Others
1.3 China Neuroendocrine Tumor Drug Market by Application/End Users
  1.3.1 China Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 China Neuroendocrine Tumor Drug Market by Region
  1.4.1 China Neuroendocrine Tumor Drug Market Size (Million USD) Comparison by Region (2012-2022)
  1.4.2 South China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
  1.4.3 East China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
  1.4.4 Southwest China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
  1.4.5 Northeast China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
  1.4.6 North China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
  1.4.7 Central China Neuroendocrine Tumor Drug Status and Prospect (2012-2022)
1.5 China Market Size (Sales and Revenue) of Neuroendocrine Tumor Drug (2012-2022)
  1.5.1 China Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2022)
  1.5.2 China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 CHINA NEUROENDOCRINE TUMOR DRUG MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 China Neuroendocrine Tumor Drug Sales and Market Share of Key Players/Manufacturers (2012-2017)
2.2 China Neuroendocrine Tumor Drug Revenue and Share by Players/Manufacturers (2012-2017)
2.3 China Neuroendocrine Tumor Drug Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
2.4 China Neuroendocrine Tumor Drug Market Competitive Situation and Trends
  2.4.1 China Neuroendocrine Tumor Drug Market Concentration Rate
  2.4.2 China Neuroendocrine Tumor Drug Market Share of Top 3 and Top 5 Players/Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion in China Market
2.5 China Players/Manufacturers Neuroendocrine Tumor Drug Manufacturing Base Distribution, Sales Area, Product Types

3 CHINA NEUROENDOCRINE TUMOR DRUG SALES AND REVENUE BY REGION (2012-2017)

3.1 China Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Region (2012-2017)
3.2 China Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Region (2012-2017)
3.3 China Neuroendocrine Tumor Drug Price (USD/Pcs) by Regions (2012-2017)

4 CHINA NEUROENDOCRINE TUMOR DRUG SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2012-2017)

4.1 China Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
4.2 China Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Type (2012-2017)
4.3 China Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2012-2017)
4.4 China Neuroendocrine Tumor Drug Sales Growth Rate (%) by Type (2012-2017)

5 CHINA NEUROENDOCRINE TUMOR DRUG SALES BY APPLICATION (2012-2017)

5.1 China Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Application (2012-2017)
5.2 China Neuroendocrine Tumor Drug Sales Growth Rate (%) by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 CHINA NEUROENDOCRINE TUMOR DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Eisai
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Exelixis, Inc.
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Foresee Pharmaceuticals, LLC
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Hutchison MediPharma Limited
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Intezyne, Inc
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.5.4 Main Business/Business Overview
6.6 INVENT Pharmaceuticals, Inc.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Ipsen S.A.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Jiangsu Hengrui Medicine Co., Ltd.
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Karyopharm Therapeutics, Inc.
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Lexicon Pharmaceuticals, Inc.
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Neuroendocrine Tumor Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Midatech Pharma Plc.
6.12 Millennium Pharmaceuticals, Inc.
6.13 MolMed S.p.A.
6.14 Northwest Biotherapeutics, Inc.
6.15 Novartis AG
6.16 OctreoPharm Sciences GmbH
6.17 OXiGENE, Inc.

7 NEUROENDOCRINE TUMOR DRUG MANUFACTURING COST ANALYSIS

7.1 Neuroendocrine Tumor Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neuroendocrine Tumor Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Neuroendocrine Tumor Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neuroendocrine Tumor Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 CHINA NEUROENDOCRINE TUMOR DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 China Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
11.2 China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Type (2017-2022)
11.3 China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
11.4 China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Global and China Market Size (Million USD) Comparison (2012-2022)
Table Neuroendocrine Tumor Drug Sales (K Pcs) and Revenue (Million USD) Market Split by Product Type
Table Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2016-2022)
Figure Product Picture of Neuroendocrine Tumor Drug
Table China Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%) Comparison by Types (Product Category) (2012-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Market Share by Types in 2016
Figure mTOR protein inhibitors Product Picture
Figure Tyrosine kinase 3 inhibitors Product Picture
Figure Somatostatin receptor antagonists Product Picture
Figure Growth hormone releasing factor antagonists Product Picture
Figure Somatostatin receptor agonists Product Picture
Figure Others Product Picture
Figure China Neuroendocrine Tumor Drug Sales (K Pcs) Comparison by Application (2012-2022)
Figure China Sales Market Share (%) of Neuroendocrine Tumor Drug by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure South China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure East China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Northeast China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure North China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Central China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure China Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2022)
Figure China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (%)(2012-2022)
Table China Neuroendocrine Tumor Drug Sales of Key Players/Manufacturers (2012-2017)
Table China Neuroendocrine Tumor Drug Sales Share (%) by Players/Manufacturers (2012-2017)
Figure 2016 China Neuroendocrine Tumor Drug Sales Share (%) by Players/Manufacturers
Figure 2017 China Neuroendocrine Tumor Drug Sales Share (%) by Players/Manufacturers
Table China Neuroendocrine Tumor Drug Revenue by Players/Manufacturers (2012-2017)
Table China Neuroendocrine Tumor Drug Revenue Market Share (%) by Players/Manufacturers (2012-2017)
Figure 2016 China Neuroendocrine Tumor Drug Revenue Market Share (%) by Players/Manufacturers
Figure 2017 China Neuroendocrine Tumor Drug Revenue Market Share (%) by Players/Manufacturers
Table China Market Neuroendocrine Tumor Drug Average Price of Key Players/Manufacturers (2012-2017)
Figure China Market Neuroendocrine Tumor Drug Average Price of Key Players/Manufacturers in 2016
Figure China Neuroendocrine Tumor Drug Market Share of Top 3 Players/Manufacturers
Figure China Neuroendocrine Tumor Drug Market Share of Top 5 Players/Manufacturers
Table China Players/Manufacturers Neuroendocrine Tumor Drug Manufacturing Base Distribution and Sales Area
Table China Players/Manufacturers Neuroendocrine Tumor Drug Product Category
Table China Neuroendocrine Tumor Drug Sales (K Pcs) by Regions (2012-2017)
Table China Neuroendocrine Tumor Drug Sales Share (%) by Regions (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Share (%) by Regions (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Market Share (%) by Regions in 2016
Table China Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Regions (2012-2017)
Table China Neuroendocrine Tumor Drug Revenue Market Share (%) by Regions (2012-2017)
Figure China Neuroendocrine Tumor Drug Revenue Market Share (%) by Regions (2012-2017)
Figure China Neuroendocrine Tumor Drug Revenue Market Share (%) by Regions in 2016
Table China Neuroendocrine Tumor Drug Price (USD/Pcs) by Regions (2012-2017)
Table China Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2012-2017)
Table China Neuroendocrine Tumor Drug Sales Share (%) by Type (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Share (%) by Type (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Market Share (%) by Type in 2016
Table China Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table China Neuroendocrine Tumor Drug Revenue Market Share (%) by Type (2012-2017)
Figure Revenue Market Share of Neuroendocrine Tumor Drug by Type (2012-2017)
Figure Revenue Market Share of Neuroendocrine Tumor Drug by Type in 2016
Table China Neuroendocrine Tumor Drug Price (USD/Pcs) by Types (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Growth Rate (%) by Type (2012-2017)
Table China Neuroendocrine Tumor Drug Sales (K Pcs) by Applications (2012-2017)
Table China Neuroendocrine Tumor Drug Sales Market Share (%) by Applications (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Market Share (%) by Application (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Market Share (%) by Application in 2016
Table China Neuroendocrine Tumor Drug Sales Growth Rate (%) by Application (2012-2017)
Figure China Neuroendocrine Tumor Drug Sales Growth Rate (%) by Application (2012-2017)
Table Eisai Neuroendocrine Tumor Drug Basic Information List
Table Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Exelixis, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Basic Information List
Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Basic Information List
Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Intezyne, Inc Neuroendocrine Tumor Drug Basic Information List
Table Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Ipsen S.A. Neuroendocrine Tumor Drug Basic Information List
Table Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Basic Information List
Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%)(2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share (%) in China (2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share (%) in China (2012-2017)
Table Midatech Pharma Plc. Neuroendocrine Tumor Drug Basic Information List
Table Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table MolMed S.p.A. Neuroendocrine Tumor Drug Basic Information List
Table Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Novartis AG Neuroendocrine Tumor Drug Basic Information List
Table OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Basic Information List
Table OXiGENE, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neuroendocrine Tumor Drug
Figure Manufacturing Process Analysis of Neuroendocrine Tumor Drug
Figure Neuroendocrine Tumor Drug Industrial Chain Analysis
Table Raw Materials Sources of Neuroendocrine Tumor Drug Major Players/Manufacturers in 2016
Table Major Buyers of Neuroendocrine Tumor Drug
Table Distributors/Traders List
Figure China Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure China Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure China Neuroendocrine Tumor Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Type (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Type (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Type in 2022
Table China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Application in 2022
Table China Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Regions (2017-2022)
Table China Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions (2017-2022)
Figure China Neuroendocrine Tumor Drug Sales Volume Share Forecast by Regions in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources